eyeforpharma Barcelona 2016 conference

eyeforpharma 15 - 17 March 2016, Barcelona, Spain.
eyeforpharma Barcelona will set the vision for your 2020 plans. With 120% attendee growth you can join 1000+ industry leaders in commercial excellence, patient engagement and innovation at the unmissable pharma-stakeholder summit. As your customer takes charge this meeting will enable you take the steps you need to become their partner of choice.

The conference will bring together all key stakeholders, so you can collaborate and identify solutions in order to:

  • Gain Real Customer Insight. Reinvent your understanding of customer experience with a holistic multichannel solution
  • Deliver Outcomes. Enhance patient experience by partnering with external stakeholders and facilitating internal cross functionality
  • Sell Value. Engage the busier, more informed customer with impactful face-to-face, remote and digital communication
  • Develop a New Corporate Culture. Pioneer a progressive internal mind-set promoting collaboration, communication and trust

Why Attend?
90+ industry leading speakers including C-Suite, VP and Director level experts to share their experiences so you can make healthier corporate decisions. 2016 speakers include:

Keynotes

  • David Epstein, Novartis, Division Head and CEO Pharmaceuticals
  • Dominique Limet, ViiV, Healthcare
  • Jane Griffiths, Janssen, Company Group Chairman, Europe, Middle East & Africa
  • Gitte Aabo, LEO Pharma, CEO
  • Eduardo Javier Sanchiz Yrazu, Almirall, CEO
  • Murray Stewart, GSK, Chief Medical Officer
  • Tim Kneen, Merck, Executive President, Europe & Canada
  • David Loew, Sanofi Pasteur, COO
  • Andrew Hotchkiss, Eli Lilly and Company, President Europe and Canada
  • Jason DeGoes, Teva, SVP Patient Solutions

Patient Experience

  • Kasper Jerlang, LEO Pharma, Head - Global Patient Communications
  • Sanja Njegic, Novartis, Director Patient Relations, Europe
  • Henrik Finnern, Boehringer Ingelheim, Chief Patient Office
  • Anne Beal, Sanofi, Chief Patient Officer
  • Paul Robinson, MSD, Executive Director Scientific Medical and Patient Perspective

Commercial Excellence

  • Andreas Wandelt, Pfizer, Vice President, Global Sales and Marketing Services
  • Heléna Bargiel, LEO Pharma, Head of Global Field Force Excellence
  • Etienne Tichit, Novo Nordisk, Vice President, Commercial Excellence
  • Bharat Tewarie, UCB, EVP & Chief Marketing Officer
  • Chris-Carol Bremer, Grunenthal, SVP & Head of Marketing

See the complete speaker line-up here.

Don't miss Barcelona 2016, Europe’s premier pharmaceutical summit in commercial excellence, patient engagement and innovation!

Save €100 using World Pharma News unique code wpn100

For further information, please visit:
http://www.eyeforpharma.com/barcelona/

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the center.

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...